November 07, 2023 (Earnings Report) Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
UpHealth
Symbol: UPH
Recent Price: $0.42
Average Analyst Price Target: $4.77 (1893.81%)
Market Cap: $16.81M
Last Year's EPS: -0.51
Consensus EPS Forecast: -0.46
Expected Earnings Date: 2023-08-10
Recent Analyst Action: Bill Sutherland, analyst at Benchmark Co., reiterates coverage on UpHealth (UPH) in the Healthcare sector with a Buy rating and a price target of $7 (1 month ago).
TipRanks.com also reports that UpHealth currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $4.77 . The target pricing ranges from a high forecast of $7 down to a low forecast of $3. UpHealth (UPH)’s last closing price was $0.42 which would put the average price target at 1893.81% upside.Here are 3rd party ratings for UPH:
Recent Analyst Action: Srikripa Devarakonda, analyst at Truist Financial, reiterates coverage on Affimed (AFMD) in the Healthcare sector with a Buy rating and a price target of n/a (4 weeks ago).
TipRanks.com also reports that Affimed currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $5.00 . The target pricing ranges from a high forecast of $6 down to a low forecast of $4. Affimed (AFMD)’s last closing price was $0.40 which would put the average price target at 1144.09% upside.Here are 3rd party ratings for AFMD:
Recent Analyst Action: Jason Bazinet, analyst at Citi, reiterates coverage on Walt Disney (DIS) in the Communication Services sector with a Buy rating and a price target of $110 (1 day ago).
TipRanks.com also reports that Walt Disney currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $104.00 . The target pricing ranges from a high forecast of $96 down to a low forecast of $100. Walt Disney (DIS)’s last closing price was $84.02 which would put the average price target at 25.71% upside.Here are 3rd party ratings for DIS:
Recent Analyst Action: Derrick Whitfield, analyst at Stifel Nicolaus, reiterates coverage on Gevo (GEVO) in the Energy sector with a Buy rating and a price target of $3.6 (2 weeks ago).
TipRanks.com also reports that Gevo currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $6.53 . The target pricing ranges from a high forecast of $3.6 down to a low forecast of $14. Gevo (GEVO)’s last closing price was $1.21 which would put the average price target at 439.67% upside.Here are 3rd party ratings for GEVO:
Recent Analyst Action: George Sutton, analyst at Craig-Hallum, reiterates coverage on Anterix (ATEX) in the Energy sector with a Buy rating and a price target of $100 (3 weeks ago).
TipRanks.com also reports that Anterix currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $70.50 . The target pricing ranges from a high forecast of $41 down to a low forecast of $100. Anterix (ATEX)’s last closing price was $30.95 which would put the average price target at 223.10% upside.Here are 3rd party ratings for ATEX:
Recent Analyst Action: Alexander Nowak, analyst at Craig-Hallum, reiterates coverage on Broadwind Energy (BWEN) in the Energy sector with a Buy rating and a price target of n/a (4 weeks ago).
TipRanks.com also reports that Broadwind Energy currently has 2 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $9.00 . The target pricing ranges from a high forecast of $6 down to a low forecast of $12. Broadwind Energy (BWEN)’s last closing price was $2.56 which would put the average price target at 251.56% upside.Here are 3rd party ratings for BWEN:
Recent Analyst Action: Colin Bristow, analyst at UBS, reiterates coverage on Biogen (BIIB) in the Healthcare sector with a Buy rating and a price target of $312 (4 days ago).
TipRanks.com also reports that Biogen currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $340.00 . The target pricing ranges from a high forecast of $361 down to a low forecast of $312. Biogen (BIIB)’s last closing price was $248.63 which would put the average price target at 29.64% upside.Here are 3rd party ratings for BIIB:
To Your Financial Future,
The Editor, WallStreetSectors.com